tiprankstipranks
Trending News
More News >
Carisma Therapeutics (CARM)
NASDAQ:CARM

Carisma Therapeutics (CARM) AI Stock Analysis

Compare
1,616 Followers

Top Page

CA

Carisma Therapeutics

(NASDAQ:CARM)

Rating:48Neutral
Price Target:
$0.50
▼(-16.67%Downside)
The overall stock score is primarily influenced by the significant financial challenges Carisma Therapeutics is facing, including unstable financial statements and negative valuation metrics. While technical analysis shows some positive momentum, these factors are outweighed by the financial and valuation concerns. The lack of earnings call details and corporate events means the score is largely driven by core financial and market data.
Positive Factors
Cash Flow and Financial Stability
The company expects its current cash runway to last through the third quarter of 2025, providing a degree of financial stability.
Partnerships and Collaborations
Carisma's focus is now on partnered programs with Moderna, including a GPC3-targeted program and a liver-fibrosis program, showing potential future growth areas.
Negative Factors
Program Discontinuation and Restructuring
Carisma announced the discontinuation of their lead HER-2 monocyte program CT-0525 due to lack of strong enrollment and evolving clinical landscape.
Rating Downgrade
The rating for Carisma has been downgraded from Buy to Neutral due to a lack of near-term catalysts and a financing overhang.

Carisma Therapeutics (CARM) vs. SPDR S&P 500 ETF (SPY)

Carisma Therapeutics Business Overview & Revenue Model

Company DescriptionCarisma Therapeutics (CARM) is a biotechnology company focused on the development of innovative cellular therapies aimed at treating cancer and other serious diseases. Utilizing its proprietary chimeric antigen receptor macrophage (CAR-M) technology, Carisma is pioneering a new class of immunotherapy treatments that harness the body's own immune system to target and eliminate cancer cells. The company's core product pipeline includes several promising candidates in various stages of clinical development, addressing unmet medical needs in oncology and beyond.
How the Company Makes MoneyCarisma Therapeutics generates revenue primarily through the development and commercialization of its proprietary CAR-M technology-based therapies. The company's revenue streams include potential product sales upon successful approval and market entry of its therapeutic candidates. Additionally, Carisma may engage in strategic collaborations and partnerships with other pharmaceutical companies, allowing for co-development, licensing agreements, and milestone payments. These partnerships provide financial support and accelerate the development of its therapeutic pipeline. Furthermore, Carisma may receive research grants and funding from governmental or non-profit organizations that support innovative cancer treatment research, contributing to its overall earnings.

Carisma Therapeutics Financial Statement Overview

Summary
Carisma Therapeutics is facing significant financial challenges. The income statement shows volatile revenue and negative profitability metrics. The balance sheet highlights instability with negative stockholders' equity and a high debt-to-equity ratio. Cash flow concerns persist with consistently negative free cash flow, indicating difficulty in generating cash from operations.
Income Statement
35
Negative
Carisma Therapeutics has shown a volatile revenue pattern, with the latest TTM revenue slightly increasing. However, the company is struggling with profitability, evident from negative EBIT and net profit margins. The negative revenue growth in recent years indicates challenges in market expansion.
Balance Sheet
20
Very Negative
The balance sheet reflects significant financial instability with negative stockholders' equity and a high debt-to-equity ratio. The negative equity ratio highlights potential solvency issues, which could pose risks to long-term sustainability.
Cash Flow
30
Negative
Cash flow analysis reveals concerns, with consistently negative free cash flow indicating challenges in generating cash from operations. The operating cash flow to net income ratio is unfavorable, suggesting difficulties in converting revenue into cash.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
19.96M19.63M14.92M9.83M26.54M11.24M
Gross Profit
19.04M19.63M-59.21M3.74M26.46M11.24M
EBIT
-52.00M-62.18M-88.73M-56.16M-40.79M-28.38M
EBITDA
-49.46M-57.12M-85.89M-51.99M-40.11M-27.93M
Net Income Common Stockholders
-50.77M-60.48M-86.88M-61.23M-40.77M-28.32M
Balance SheetCash, Cash Equivalents and Short-Term Investments
7.74M17.91M77.61M52.00M28.55M51.79M
Total Assets
15.95M30.46M89.55M72.15M35.45M58.46M
Total Debt
2.33M2.48M3.12M40.16M2.63M3.44M
Net Debt
-5.42M-15.43M-74.48M15.97M-25.92M-48.34M
Total Liabilities
52.62M58.37M63.02M101.28M9.43M8.31M
Stockholders Equity
-36.66M-27.91M26.53M-49.26M11.63M35.76M
Cash FlowFree Cash Flow
-47.66M-60.04M-82.31M-12.23M-39.20M-27.45M
Operating Cash Flow
-47.56M-59.92M-81.18M-7.57M-37.33M-27.01M
Investing Cash Flow
418.00K-123.00K72.41M-32.56M-1.87M-440.00K
Financing Cash Flow
-1.63M344.00K62.18M35.77M15.96M72.26M

Carisma Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.60
Price Trends
50DMA
0.23
Positive
100DMA
0.33
Positive
200DMA
0.59
Positive
Market Momentum
MACD
0.08
Negative
RSI
61.43
Neutral
STOCH
73.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CARM, the sentiment is Positive. The current price of 0.6 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.23, and above the 200-day MA of 0.59, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 61.43 is Neutral, neither overbought nor oversold. The STOCH value of 73.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CARM.

Carisma Therapeutics Risk Analysis

Carisma Therapeutics disclosed 82 risk factors in its most recent earnings report. Carisma Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Carisma Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$10.17M4.67-41.13%
54
Neutral
$5.38B3.40-45.06%3.28%16.75%-0.02%
49
Neutral
$9.42M-451.34%-57.84%
48
Neutral
$46.38M-362.79%32.45%39.31%
39
Underperform
$8.30M-285.79%23.65%
34
Underperform
$8.40M-126.03%-100.00%-27.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CARM
Carisma Therapeutics
0.60
-0.57
-48.72%
KPRX
Kiora Pharmaceuticals
3.16
-1.76
-35.77%
DWTX
Dogwood Therapeutics
4.82
-0.90
-15.73%
ACXP
Acurx Pharmaceuticals
0.35
-2.14
-85.94%
TSBX
Turnstone Biologics Corp.
0.36
-2.48
-87.32%

Carisma Therapeutics Corporate Events

Delistings and Listing ChangesRegulatory Filings and Compliance
Carisma Therapeutics Secures Nasdaq Listing Approval
Neutral
Jun 12, 2025

On June 10, 2025, Carisma Therapeutics received approval from a Nasdaq Hearings Panel to continue its listing on Nasdaq, with the listing being transferred to the Nasdaq Capital Market effective June 12, 2025. Despite previous non-compliance with Nasdaq’s listing rules, the company has been granted an extension until October 7, 2025, to meet specific conditions, including maintaining a minimum bid price and completing a strategic transaction, to ensure continued listing.

The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.